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ABSTRACT 
Current experimental methodologies used to determine the thermodynamic 
solubility of an API within a polymer typically involves establishing the 
dissolution/melting endpoint of the crystalline API within a physical mixture, or 
through the use of the glass transition temperature measurement of a de-
mixed amorphous solid dispersion. The measurable “equilibrium” points for 
solubility are normally well above the glass transition temperature of the 
system meaning extrapolation is required in order to predict the drug solubility 
at pharmaceutical relevant temperatures. In this manuscript we argue that, the 
presence of highly viscous polymers in these systems results in experimental 
data that exhibits an under or over estimated value relative to the true 
thermodynamic solubility. In previous work we demonstrated the effects of 
experimental conditions and their impact on measured and predicted 
thermodynamic solubility points. In the light of current understanding, we have 
developed a new method to limit error associated with viscosity effects for the 
application in small-scale hot-melt extrusion (HME). In this study HME was 
used to generate an intermediate (multi-phase) system containing crystalline 
drug, amorphous drug/polymer rich regions as well as drug that was 
molecularly dispersed in polymer. An extended annealing method was used 
together with high-speed differential scanning calorimetry to accurately 
determine the upper and lower boundary of the thermodynamic solubility of a 
model drug –polymer system (felodipine and Soluplus®). Comparing to our 
previously published data, the current results confirmed our hypothesis that 
the prediction of the liquid-solid curve using dynamic determination of 
dissolution/melting endpoint of the crystalline API physical mixture presents 
an under estimation relative to the thermodynamic solubility point. With this 
proposed method, we were able to experimentally measure the upper and 
lower boundary of liquid-solid curve for the model system. The relationship 
between inverse temperature and drug-polymer solubility parameter (χ) 
remained linear at lower drug loadings. Significant higher solubility and 
miscibility between felodipine-Soluplus® system were derived from the new χ 
values.   
 
  
3	
	
INTRODUCTION 
Amorphous solid dispersions (ASDs) are one of several enabling formulation 
strategies employed to overcome the poor aqueous solubility of BCS class 
II/IV drugs. The feasibility of the amorphous form to enhance solubility and 
dissolution performance is routinely assessed from pre-formulation stages to 
late clinical trial1. Interestingly, despite significant research having been 
conducted in the area of ASDs the selection of excipients including polymers 
for this purpose is still largely based on a trial and error approach. An added 
complexity in formulating ASDs is in selection of an appropriate manufacturing 
method. ASDs have been commonly manufactured using spray-drying or hot 
melt extrusion (HME). Recently HME has received considerable attention due 
to it being continuous in nature, it is solvent-free and permits ease of scale. 
However, HME is relatively complex in that an operator may change a number 
of process variables (e.g., feed rate, screw speed, barrel temperature, screw 
design), which may impact upon the final quality of the ASD. Therefore, the 
successful manufacture of an ASD using HME requires a rational approach to 
formulation design, processing and parameter selection. 
 
The application of the Flory-Huggins (F-H) theory to produce thermodynamic 
phase diagrams has gone some way to provide improved understanding of 
the solubility of drug in both small molecular matrix (1, 2) and large polymeric 
dispersion systems (3-6). This method has the potential to be used to identify 
design space for the manufacture of stable ASD systems, particularly for non-
ambient processes such as HME and may help to reduce the cost of drug 
product manufacture (7). Currently, the experimental methodologies used to 
understand drug solubility in polymeric carriers comprises two principal 
approaches; the ‘thermodynamic’ equilibrium point determined from 
dissolution/melting of a crystalline drug in a polymer/drug physical mixture or 
the ‘thermodynamic’ equilibrium point determined from a de-mixed 
supersaturated amorphous polymer/drug solid dispersion (8-10). To explain 
this further, a thermodynamic phase diagram shown in Figure 1 depicts a 
black solid line as the true thermodynamic drug solubility equilibrium curve in 
respect to the polymer. This indicates the lowest energy for the mixture. In 
both methods a dynamic heating approach is normally used, and the 
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dissolution/melting of the crystalline drug within the physical mixture or the 
glass transition temperature of the de-mixed amorphous solid dispersion may 
be identified using differential scanning calorimetry (DSC). The de-mixing 
method, involves a supersaturated amorphous solid dispersion (amorphous 
polymer with a drug loading ≥ 80% w/w) which is annealed at a range of 
temperatures that are lower than the melting point of the drug and higher than 
the glass transition temperature of the system (10). Therefore, the 
supersaturated amorphous system undergoes de-mixing to lower energy (via 
direction a to e in Figure 1). After de-mixing (reported to be approximately 4 
hours for an indomethacin-PVP system (11)) the temperature of the single 
glass transition is used to calculate drug solubility from a constructed drug-
polymer Tg-composition curve. In contrast, the dissolution/melting endpoint 
measurement method measures the end point of the dissolution/melting 
temperature of crystalline drug within physical mixtures of polymer at a 
constant heating rate (via direction of c to e in Figure 1). In both approaches, 
although careful sample preparation and judicious choice of experimental 
conditions can improve the accuracy of both methods, the presence of highly 
viscous polymeric materials significantly impacts upon the determination of 
thermodynamic equilibrium solubility values. For example, in using the de-
mixing method, a phase separated two Tg system may be observed after a 
prolonged period of annealing (12, 13). The appearance of amorphous-
amorphous systems is the initial indication of a non-equilibrium state of the 
de-mixing process due to the presence of high viscosity polymers, thus 
extended de-mixing times may be required for the full crystallisation of an 
amorphous-amorphous system. Achievement of equilibrium in such systems 
may be require a long period of time, particularly at the latter stages of the de-
mixing process due to this isothermal experimental design and a 
progressively increasing viscosity. The measured data may therefore 
overestimate the true thermodynamic equilibrium solubility (dash line, Figure 
1). Furthermore, different preparation techniques (milling, film casting or spray 
drying) may also introduce differences in the initial state of the amorphous 
system, in which the rate of de-mixing will vary (14, 15). In this study, attempts 
were made to utilize the de-mixing method for determination of the equilibrium 
solubility in a FD-Soluplus system. However, for an 80% w/w FD-Soluplus 
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ASD prepared by DSC quench-cooling, annealing at 120°C required at least 8 
hours to generate a distinctive glass transition with the presence of a small 
drug melting peak. Moreover, the use of Tg values for the determination of 
drug composition is extremely difficult as amorphous FD and Soluplus exhibit 
glass transition values within 30°C of each other and the signal to noise ratio 
at high drug loading is very low (data shown in supporting documentation). 
For other systems a de-mixing method may be entirely inappropriate, i.e. 
felodipine, celecoxib or indomethacin with low Tg polymers (Eudragit EPO®) 
where the Tg of the polymer is indistinguishable to the Tg of the amorphous 
drug (16). In comparison, the accuracy of the measurement when using the 
dissolution/melting endpoint method may be improved by suitable sample 
preparation and the use of slow heating rates (17). Common methods of 
preparing drug and polymer mixtures before DSC analysis include ball milling 
and cryomilling. The main advantage of milling and mixing is that the effects 
of diffusive mixing are reduced and a more accurate value of the 
dissolution/melting endpoint may be obtained. A greater extent of 
homogeneity is often obtained when samples are prepared via milling as 
opposed to physical mixing using a mortar and pestle. The reduction in the 
effects of diffusive mixing improves crystalline drug dissolution kinetics, and 
the prediction of the thermodynamic solubility curve may be more accurate. 
The completion of dissolution will always be delayed however by the presence 
of a viscous polymeric material; thus the measured temperature for the 
endpoint may be greater than the true thermodynamic equilibrium curve (dash 
dot line).  This results in an underestimation of drug solubility in polymer as 
shown in Figure 1.  
 
Despite the variation in the data generated by the alternative approaches 
described above, both can provide useful information regarding the evaluation 
of the drug-polymer interaction parameter, and the relevance of temperature 
and drug composition upon the miscibility within binary amorphous solid 
dispersions. Thermodynamic phase diagrams together with an appreciation of 
the dynamics of amorphous drug crystallisation can be used to further 
improve our understanding of the manufacturing process and phase stability 
of binary amorphous drug-polymer solid dispersion systems (18, 19). The 
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construction of thermodynamic drug-polymer temperature-composition phase 
diagrams relies heavily on the empirical relationship that exists between the 
drug-polymer interaction parameter, χ, and the temperature, T. As a result of 
slow heating rates (< 5°C/min) employed in the dynamic dissolution/melting 
endpoint approach, it is common that melting point depression data can be 
obtained only at drug loadings greater than 70% w/w if the system exhibits 
favourable miscibility (20, 21). In order to complete the liquid-solid transition 
curve, the relationship between χ and 1/T is utilised to determine the entropic 
(A) and enthalpic (B) contributions to χ, so the interaction parameter can be 
calculated for any temperature below the limit of detection in the DSC (eq.1).  
 
T
BApolydrug       (1) 
 
The extrapolation of the solubility curve is dependent on the assumption of A 
and B calculated on the basis of a linear relationship between χ and 1/T. To 
date, all drug-polymer phase diagrams completed in the literature have 
exhibited Upper Critical Solution Temperature (UCST) behaviour (5, 8, 22) 
where A < 0 and B > 0. This situation arises when the value of the interaction 
parameter decreases as temperature is increased. An example of a plot of χ 
vs. 1/T associated to UCST behaviour can be observed in Figure 2. From 
such a plot, it would be extremely desirable to obtain drug solubility data at 
lower temperatures. The attainment of additional data points beyond 
previously accepted limits of detection would undoubtedly further our 
understanding of crystalline drug solubility and amorphous drug miscibility 
within the polymer. Consequently, the extension of our understanding of χ vs. 
1/T will enable further evaluation of whether UCST behaviour adequately 
describes the drug-polymer system at the lower temperature range (23).  
 
In this article we utilise HME in an attempt to address the aspects described 
above and to generate a highly mixed drug polymer solid dispersion 
containing multi-phases. Using this approach, in combination with high 
heating rates to determine crystalline content, will provide useful insights for 
the determination of the liquid-solid boundary beyond the current limit of 
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understanding and those developed thus far using the two aforementioned 
methods. Furthermore, the multi-phase system and annealing results may 
help provide a clearer understanding of drug-polymer miscibility and 
importantly, the impact that processing conditions may have upon the drug 
polymer platform.  
 
MATERIALS AND METHODS  
Crystalline felodipine (FD) form I was purchased from Taresh Chemicals Ltd. 
(Co. Down, UK) and used without further purification. Polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer (brand name Soluplus®) 
was obtained from BASF Chemical Co. (Ludwigshafen, Germany).  Samples 
were kept in a temperature controlled vacuum oven (50ºC) for at least two 
days prior to experiments. 
 
Ball Milling 
Ball milling was performed at room temperature using a Retsch MM200 
oscillatory ball mill (Mohrengasse, Germany). A physical mixture (1g) 
containing 60% w/w felodipine was prepared and placed into a 25 mL milling 
chamber with a single stainless steel ball (Φ=15mm) and milled at 20Hz. A 
milling cycle of two minutes was followed by a stationary period of two 
minutes. In total, 8 minutes of ball milling were completed. This period of ball 
milling has previously been found to maximise the particle surface interaction 
between felodipine and Soluplus® and render the drug partially amorphous 
(5).   
 
Hot-Melt Extrusion  
A fractional 2-level scope design incorporating drug load (50-70% w/w FD), 
screw speed (11-30rpm), 90° mixing elements (0-3) and 60° mixing elements 
(0-3) was examined. Screening of these parameters was used to determine 
the significance of each factor on drug-polymer mixing and crystalline content 
(Design Expert 9, Stat-Ease Inc., MN, USA). These experimental variables 
were identified as the key parameters that would influence drug-polymer 
interaction when processed via a co-rotating 10mm twin-screw hot-melt 
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extruder (Microlab10mm, Rondol, France). The 2-level scope design 
produced the experimental design detailed in Table 1. Drug and polymer 
mixtures (5 g) were initially hand mixed with a pestle and mortar. These 
physical mixtures containing 50% and 70% w/w FD were then fed into the 
extruder, which was maintained at a temperature of 130°C. 
 
After carefully selecting the screw configuration and speed, extrudates were 
manufactured containing 60-90% w/w felodipine with Soluplus® at a 
temperature of 130°C (Tg ≤ Tprocess ≤ Tend) and a screw speed of 11rpm. The 
intension of using the HME to prepare the mixture is to produce a multiple 
phase system consisting of amorphous drug, amorphous polymer, crystalline 
drug and amorphous drug-polymer solid dispersion, therefore, the feeding 
rate was kept at slow speed (5 mg/min) to maximize the natural convey from 
twin screw extrusion process. The prepared mixture can also be benefited 
from zero moisture content, which may be considered as important factor in 
determination of drug-polymer equilibrium point in thermal analysis. 
 
The extruder was not fitted with a die to limit the backpressure and to 
maximise yield.  Extrusion at these conditions ensured that residual crystalline 
felodipine remained in the formulation. Each extrudate sample was then 
characterised using high performance differential scanning calorimetry 
(HyperDSC) and Raman chemical imaging. 
 
Thermal Analysis 
Differential scanning calorimetry (DSC 8000 Perkin-Elmer, United Kingdom) 
was used throughout this study for dissolution/melting endpoint determination. 
For dissolution/melting endpoint experiments, 1°C/min was used. Extrudates 
containing 70-90% w/w felodipine manufactured using a full conveying set-up 
were scanned to evaluate the effects of sample preparation by HME as 
opposed to ball milling through analysis of the heat of fusion (ΔHfus) of the 
respective FD melting endotherms. At this low heating rate, nitrogen was 
selected as the purge gas and the temperature and cell constant calibration 
were carried out using high purity indium, lead and zinc. 
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Following extrusion (full conveying), samples were annealed at elevated 
temperatures for a period of 24 hours. During isothermal annealing, the heat 
flow as a function of time was evaluated. Using this approach, endothermic or 
exothermic transitions were expected due to dissolution of crystalline drug into 
the mixture or recrystallisation of amorphous drug from the mixture, 
respectively.  
High heating ramp rates utilizing power compensation were used following 
annealing. In brief, samples were rapidly equilibrated to -60°C and ramped to 
200°C at a rate of 200 ºC/min in an attempt to detect any remaining crystalline 
FD. As a comparison, freshly extruded samples were also examined using the 
same heating rate. Helium was used as a purge gas at a flow rate of 40 
ml/min. Calibration of the instrument at this heating rate was completed using 
indium, lead and zinc reference samples. In all DSC analyses, samples 
weighing as close to 5.5 mg were placed into aluminium sample pans with a 
crimped pinhole lid. To ensure annealing (124-139°C) did not result in 
degradation of the sample, heat and hold experiments were performed using 
thermogravimetric analysis (TGA, TA Instruments, United Kingdom) over a 
time period of 24 hours and the weight loss of each formulation was 
determined to be less than 1% (attributed to the water loss).  
 
Powder X-Ray Diffraction (PXRD) 
The polymorphic form of drug within extrudates was evaluated using a 
MiniFlex II powder X-Ray diffractometer (Rigaku, United States). The radiation 
was generated from a copper source operating at 40kV and 40mA. The FD-
Soluplus® samples were cryomilled and packed onto a zero background 
sample holder and scanned from 0° to 40° 2θ, using a step width of 0.01° 2θ 
and a scanning rate of 1°/min in continuous mode. 
 
Raman Chemical Mapping 
Extruded FD-Soluplus® samples were pressed onto aluminum discs and 
Raman Mapping was performed using a Raman Microscope 300 (Perkin 
Elmer, United Kingdom). All analyses were completed using an exposure time 
of 6 seconds (3 x 2s) in the wavenumber range from 200-3200 cm-1. Mapping 
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areas of approximately 400 µm2 were obtained using a x20 objective with a 
laser diameter of 50 μm and spacing of 25 μm. Spectral data analysis was 
performed using Grams/AI version 7.02 from Thermo GalacticTM (Waltham, 
MA). Maps produced using this methodology were compared to the spectrum 
of pure crystalline FD and correlation factors were calculated using Raman 
Image software. 
 
Rheological Characterisation 
The dynamic viscosities of FD-Sol mixtures at 1Hz were determined using an 
AR2000 Rheometer (TA Instruments, United Kingdom). Physical mixtures 
weighing 250 mg were loaded on to a lower stationary plate held at 145 °C. 
An upper geometry consisting of a 20mm parallel plate was employed with the 
gap between the upper and lower plates set at 400 µm. The samples were 
allowed to equilibrate at 145 °C for a period of 5 minutes. When this time had 
elapsed, the samples were cooled at a rate of 5°C/min to the target 
temperature of 125 °C. An oscillatory stress, selected from the linear 
viscoelastic region, of 5 Pa, was employed for these non-destructive tests. 
This test was selected to represent the conditions similar to the DSC 
annealing study. 
 
Construction of Phase Diagram 
An in-depth discussion of the theory behind the construction of 
thermodynamic drug-polymer phase diagrams is provided in our previous 
published articles and hence only a brief explanation is given here (5, 8). The 
midpoint values of the upper and lower boundaries identified from annealing 
were used in equation 1 to determine the respective χ values at each 
temperature. 


 

  
2
0
11ln11 polypolydrugpolydrug
mm mH
R
TT
    (2) 
 
A plot of χ versus 1/T enabled calculation of the associated entropic (A) and 
enthalpic (B) contributions to χ (eq1). The determination of these values 
facilitated the extrapolation of the remainder of the liquid-solid transition curve 
11	
	
at points beyond the limit of experimental detection. The position of the 
spinodal curve was constructed by calculating the second derivative of 
equation 4 and equating to zero (24) 
 
mixmixmix STHG     (3) 
 



   polydrugpolydrugpolypolydrugdrugmix mRTG 
 lnln  (4) 
Substitution of the previously calculated values of A and B into the second 
derivative of equation 2 enabled a series of theoretical spinodal curve 
temperatures to be calculated for a range of drug volume fractions. 
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RESULTS AND DISCUSSION 
 
As the pre-mixing technique used in this study was HME, Soluplus® was an 
ideal excipient due to its low Tg (80°C) and suitable melt flow at a temperature 
of 130°C. At this extrusion temperature, the polymer will be in its rubbery 
state, however the drug will not have exceeded its melting point. Theoretically, 
as the materials are conveyed through the barrel of the extruder, the 
crystalline drug will be mixed throughout the rubbery polymeric matrix. 
However, the shear stresses produced by the mixing action of the co-rotating 
screws could potentially cause felodipine to be rendered partially amorphous 
and encourage dissolution in the polymer matrix (25). It is also possible that 
during extrusion drug could solubilise depending on the solubility of the drug-
polymer system. The purpose of employing a 2-level fractional factorial design 
was to rapidly understand the effect of screw configuration on the residual 
crystalline content of FD-Sol extrudates. The application of the factorial design 
(24-1) resulted in 8 extrusion trials. Each extrudate from this DoE was 
analysed using a combination of HyperDSC and Raman Spectroscopy. In 
each trial we were interested in determining whether there was crystalline 
felodipine present post-extrusion (Table 1). 
 
Characterisation of Melt Extrudates 
The incorporation of mixing elements (60 or 90°) to the screw configuration at 
a temperature of 130°C led to the production of an amorphous solid 
dispersion for 50% FD-Sol. When a full conveying screw configuration was 
used crystalline FD was detected in all extrudates, demonstrating the 
effectiveness of 90° and 60° kneading elements in generating amorphous 
content and/or drug dissolution in the polymer. This observation holds 
significance to the production of ASDs via non-ambient processing (26). By 
incorporating mixing elements, lower extrusion temperatures can be selected, 
yet amorphous solid dispersions may still be produced as a result of the shear 
imparted by the mixing elements. 
 
Based upon observations made during our initial DoE, a full conveying screw 
configuration was used to manufacture 50-90% w/w FD-Sol mixtures. This 
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was essential in attempting to detect the position of the liquid-solid transition 
curve at low drug loadings i.e. 50% w/w FD. It would have been possible to 
use mixing elements at higher drug loads, since crystalline FD would still be 
present, post-processing. However, in the interests of continuity in the pre-
mixing stage, no kneading elements were utilised when extruding these 
mixtures. Upon exiting the extruder, fresh samples of FD-Sol ranging from 50-
75% w/w drug were characterised using both Raman chemical mapping and 
HyperDSC. Extrudate samples were mapped and correlated to the spectrum 
of pure crystalline FD with a high correlation being represented by red or 
white in the rainbow lookup table. The presence of crystalline FD (Form I) was 
evident in Raman maps of samples (Figure 3). The presence of amorphous 
FD was also evident in Raman maps shown in support information. The heat 
of fusion from melting of residual crystalline FD was also evident in each 
sample using HyperDSC conducted at 200°C/min (Figure 4). The areas 
showing high correlation to reference crystalline FD spectrum indicate the 
presence of crystalline FD (red - white), whilst the areas showing low 
correlation to reference crystalline (opposite colour map in Figure 3) are 
general representing the amorphous FD (supporting information). The 
intension of producing a multi-phase system consisting of amorphous drug, 
crystalline drug, and amorphous drug-polymer solid dispersion has been 
achieved. 
 
An isothermal annealing experiment at elevated temperatures followed by a 
DSC temperature ramp (typically conducted at a heating rate of 10 °C/min), to 
analyse residual crystal content, has previously been utilized to determine the 
equilibrium solubility of drug in polymer (17). It is noted however, that under 
low heating rates within the DSC, there are at least two events occurring 
simultaneously, dissolution of drug into the polymer carrier and melting of 
crystalline drug. The dissolution of crystalline drug into polymer may occur 
when the temperature exceeds the Tg of the polymer (amorphous drug-
polymer mixture), which is lower than its crystalline melting temperature. It is 
possible that a relatively low heating rate such as 10 °C/min could therefore 
facilitate the dissolution of crystalline drug into polymer and a melting 
endotherm may not be detectable. In contrast, using high speed DSC and 
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Raman mapping, detection of crystalline content in extrudates containing low 
drug loads (55% and 50% w/w) is possible, e.g. for 50% w/w FD-Soluplus 
extrudate, a heat of fusion peak (ΔHfus≈0.19 J/g) was observed and crystalline 
FD domains, approximately 50 μm, were observed. Additionally, PXRD was 
utilized and peaks (Figure 5) characteristic of crystalline felodipine (Form I) 
were observed in the samples containing 60-90% w/w drug however it was 
difficult to verify the presence of crystalline felodopine in the extrudates 
containing at drug loadings of 55% and 50% w/w. 
The magnitude of the heat of fusion is significantly influenced by the sample 
preparation technique (Figure 6). For example, a ball milled sample with a 
drug loading of 90% w/w FD produces a ΔHfus value of 30.79 J/g at heating 
rate of 1°C/min. However, significantly lower energy (9.25 J/g) is required to 
cause fusion of felodipine within an extruded sample containing the same 
drug loading. Similar effects are observed in the samples containing other 
drug loadings. These findings indicate that hot-melt extrusion provides greater 
mixing of drug and polymer to a state where the drugs are readily solubilised 
within the polymer matrix prior or during the DSC experiment. The process of 
HME therefore induced a greater degree of miscibility between drug and 
polymer when compared to ball milling. Moreover, the effects of diffusive 
mixing are minimised within the samples prepared via HME as opposed to 
ball milling. For the purposes of this study, a 24-hour annealing time was 
applied to all extruded samples and the heat flow baseline was monitored so 
that the position of equilibrium solubility could be plotted with greater 
confidence. 
 
Experimental determination of liquid-solid transition curve 
Figure 7 illustrates thermograms for 65% and 60% FD-Sol melt extrudates 
using the extended annealing approach and high heating rates (200 °C/min). 
The initial high speed DSC scans for both melt extrudates confirmed the 
presence of a multi-phase system consisting of amorphous drug, polymer, 
mixed drug and polymer and crystalline drug (Figure 7a (number 1 and 5)). To 
experimentally detect the boundary for liquid-solid transition curve of FD-Sol 
at different drug loadings, an extended annealing experiment was carried out 
at various temperatures. When a suitable temperature was applied at defined 
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drug loading, the system will rest in equilibrium state indicating by a stable 
heat flow curve (as function of time) in the DSC thermogram. For example, as 
shown in the Figure 7a, after extended annealing at different temperatures, 
specifically 125°C (Figure 7a-2), 127°C (Figure 7a-3) and 130°C (Figure 7a-4) 
for 65% w/w drug loading and 123°C (Figure 7a-6) and 125°C (Figure 7a-7) 
for 60% w/w felodipine loading, respectively. It is clear that a single-phase 
system was generally observed with distinctive glass transitions and absence 
of melting endotherm peak when higher annealing temperature was applied 
(Figure 7a-4,7). For the 65% w/w drug loaded system, a melting endothermic 
peak was observed at annealing temperatures of 125°C and 127°C, whilst a 
small endothermic peak was observed at 123°C for the 60% drug loaded 
system. Increasing the temperature to 130°C for 65% and 125°C for 60% 
drug loaded samples, respectively, there were no melting endotherms 
observed indicating complete dissolution of drug into the polymer (much lower 
than the melting temperature of pure felodipine). The aim of annealing the 
sample at different temperatures was to define the lowest temperature 
required to fully solubilise drug in polymer. Therefore, at this temperature and 
drug loading, the amorphous solid solution is at its equilibrium state, i.e. the 
lowest Gibbs free energy state (ΔG < 0) of the binary system. It is noted that 
the melting of crystalline FD lattice is an endothermic event however, the 
annealing temperatures utilised in this study are well below melting point of 
the drug (T<Tm). Thus a dissolution event rather than a melting of drug 
predominates during annealing. An exothermic heat flow therefore may be 
expected during the isothermal annealing as the crystalline FD continuously 
dissolves within the polymer until a saturated homogenous solid solution is 
obtained (ΔH-TΔS < 0). With this in mind, a followed high speed scan can be 
used to identify the presence of undissolved crystalline FD. As demonstrated 
in Figure 7b, for both 65% and 60% drug loaded systems, an exothermic heat 
flow curve (endothermic up, zero heatflow is marked in dash line) was 
observed at all selected temperatures corresponding to the Figure 7a, 
however only samples annealed at the higher temperatures (130°C for 65% 
w/w and 125 for 60% w/w) will exhibit a single glass transition with the 
absence of melting event (Figure 7a-4,7). It would also be expected that 
crystalline FD within the extrudate would promote the process of 
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recrystallisation/drug-polymer de-mixing if the annealing temperature was 
below the liquid-solid line (27, 28). Using these findings for the 65% drug 
loaded sample it is clear that the experimental liquid-solid transition line exists 
within the region of 127-130°C, i.e. the boundary of the liquid-solid transition 
curve may be obtained. TGA analysis verified that these isothermal time 
periods within the solubilisation regime did not result in the thermal 
degradation of drug. 
 
The selected annealing temperatures for extrudates containing 60%-90% w/w 
felodipine can be found in Table 2. With this data, the position of the liquid-
solid transition curve for FD-Sol was experimentally constructed at lower drug 
loadings than previously published data. Using the original phase diagram 
constructed by ball milling followed by thermal analysis (1°C/min) and 
application of the FH theory (5), a comparison can be made between the 
positions of the liquid-solid transition curves produced by each method (Figure 
8). Indeed, our hypothesis has been confirmed that the liquid-solid line 
produced using the dynamic approach resulted in an underestimation of the 
equilibrium solubility of felodpine within Soluplus when compared to the data 
obtained using the current method. For example, the methodology laid out in 
this study found that the liquid-solid transition curve existed between 137 and 
139°C at a composition of 90% w/w drug loading, whereas the dynamic 
approach previous described by our group has identified the equilibrium 
solubility at approximately 141°C at the same drug loading. Similarly at 70% 
w/w felodipine loading, a melting point of approximately 135°C was identified 
previously, whereas this study located the liquid-solid line between 130 and 
133°C. 
 
The underestimation in equilibrium drug solubility predicted by the F-H theory 
has previously been discussed (8, 29). Insufficient drug-polymer mixing, 
produced by the process of ball milling has been found to strongly influence 
values of Tend when DSC heating rate is varied. Careful consideration of the 
selection of DSC heating rate when utilising the melting point depression 
approach is therefore essential. Increased DSC heating rates will result in the 
broadening of endothermic melting events and will produce lower values of 
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crystalline drug solubility and amorphous drug miscibility than would have 
perhaps been expected. Application of common DSC heating rates 0.2-
10°C/min will also result in varying times above the Tg of the parent polymer. 
By extending this time within the solubilisation regime, it is possible that drug 
dissolution into the polymeric carrier will be enhanced at lower DSC heating 
rates. However, it is also suggested that the intensive drug-polymer mixing 
that takes place within the extruder barrel will reduce the inhibitory effects of 
diffusive mixing when the samples are annealed in the DSC. Furthermore, an 
isothermal period of 24 hours is expected to provide a sufficient time frame to 
allow the dissolution of the crystalline drug into the polymeric matrix when 
compared to traditional DSC timescales. This may seem excessive, however 
this study aimed to identify the extent of the crystalline solubility 
underestimation and performing this annealing stage was essential in this 
process. Lastly, this methodology is not affected by the thermal lag between 
sample and reference pans as a result of increasing heating rate. The 
modified technique, using HyperDSC to detect for the presence of crystalline 
felodipine, has provided an improvement in identification of boundary for the 
drug solubility curve of felodipine-Soluplus blends. 
 
Rheological evaluation 
The effects of polymer viscosity also have to be considered when 
experimentally determining the position of the liquid-solid transition curve 
using thermal analysis techniques. Increasing polymer content results in an 
increase in viscosity of the drug-polymer mixture. Sun et al. (2010) found that 
their improved analytical method (annealing between 4 and 10 hours followed 
by a 10°C/min DSC scan) produced a liquid-solid transition curve 
approximately 7°C lower than that determined by a DSC scanning approach, 
extrapolated to zero heating rate, for mixtures containing 30% and 40% drug 
(17). The discrepancies identified at these relatively low drug loadings were 
attributed to the effects of polymer viscosity. With increased viscosity, it is 
imperative that drug-polymer mixtures are given sufficient time to reach 
equilibrium solubility. Otherwise, reduced molecular mobility will hinder the 
dissolution of the drug within the polymer and equilibrium may not be 
achieved within the limited time frame provided by a standard DSC heat ramp. 
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The dynamic viscosities of felodipine-Soluplus amorphous solid dispersions 
within the solubilisation regime of this system are shown in Figure 9. With 
decreasing drug load, it can be observed that significant increases in dynamic 
viscosity are produced across the temperature range of 125-145°C. For 
example, the dynamic viscosity of 90% w/w drug loaded sample at the 
processing temperature of 130°C is approximately 340 Pa.s. However, the 
dynamic viscosity of 50% w/w FD-Sol at the same temperature was found to 
be in excess of 4000 Pa.s. It is noted that the rheological methodology 
employed in this work involves producing ASDs at elevated temperatures 
before calculating dynamic viscosity. By melting the drug within the rubbery 
polymer, it is likely that the drug will plasticise the polymeric carrier. This does 
not mirror the HME process that has been applied in this study; instead this 
information provides an indication of the viscosity values of the plasticised 
polymer and drug mixtures at various drug loadings. Nevertheless, such a 
significant increase in dynamic viscosity with polymer content illustrates how 
an underestimation in the position of the liquid-solid transition curve may be 
obtained within the timescales of dynamic DSC single scan techniques. With 
such large dynamic viscosity values being measured when polymer content is 
increased, extended annealing times at elevated temperatures above polymer 
Tg will encourage the dissolution of the drug into the polymeric matrix and the 
likelihood of the attainment of equilibrium solubility will be enhanced. In this 
study, all of the upper boundaries of the liquid-solid transition curve exhibited 
a single Tg upon heating at 200°C/min after annealing and did not possess 
melting endotherms relating to crystalline felodipine. These findings suggest 
that the annealing periods of 24 hours at the temperatures specified in Table 
1 are not only sufficient to overcome the effects of polymer viscosity but have 
also produced a single equilibrium drug-polymer phase. 
 
Construction of thermodynamic drug-polymer phase diagram 
The identification of the upper and lower boundaries of the liquid-solid curve 
has been completed for felodipine loadings between 60-90% w/w whereas 
melting point depression data had only been detected for felodione-Soluplus 
systems as low as 70% w/w in a previous study. By inputting the midpoint 
values of the upper and lower boundaries of the liquid solid curve into 
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equation 1, a range of χ values were collected. In order to calculate the 
entropic (A) and enthalpic (B) contributions to, a plot of χ versus 1/T was 
constructed, as shown in Figure 10. 
 
It can be observed from Figure 10, a comparison of the values of χ at the 
same drug load that the methodology developed in this study not only 
produced more negative χ values for drug-polymer system but also exhibited 
a lower slope (B values) in equation 1 when compared to the dynamic 
method. Furthermore, the whole position of the curve has moved to lower 
temperatures relative to our previously published results, obtained using a 
dynamic method. This may be used to further support our postulation that, in 
the dissolution/melting point approach, the viscosity of the polymer will delay 
the completion of drug melting process, hence a higher temperature is 
normally observed. Although negative χ values do signify the existence of 
numerous adhesive bonds between the drug and polymer, larger, more 
negative values of the interaction parameter give an indication of a more 
favourable thermodynamic driving force towards the miscibility of the drug and 
polymer at temperatures close to the melting point of the drug.  
 
Such discrepancies in the χ values of the same drug-polymer system have 
previously been discussed. Sun et al. 2010 reported a χ value for Nifedipine-
PVPK12 system as -2.5 (17) whereas Marsac et al. 2009 (4) calculated the 
single χ value for this drug-polymer mixture as 0. The differences in the 
calculations were attributed to the methodology used to determine the values 
of crystalline solubility in the polymer. A negative χ value was calculated when 
cryomilling was used to pre-mix the drug and polymer, followed by annealing 
at elevated temperatures for timescales ranging between 4 and 10 hours. 
However, the dynamic approach of scanning physical mixtures at 1.0°C/min to 
elucidate melting point depression data resulted in a value of χ=0 being 
calculated for the Nifedipine-PVPK12 system. It was rationalised that 
cryomilling produced a greater degree of uniformity and a reduction in particle 
size of the drug-polymer system. Furthermore, annealing of these samples at 
times exceeding traditional DSC timescales facilitated drug dissolution at 
lower temperatures than identified via a dynamic approach. These effects 
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describe the situation in this study where the incorporation of HME, extended 
annealing periods and HyperDSC resulted in more negative χ values than the 
dissolution/melting point approach. By ramping physical mixtures using DSC 
heat scans, as a result of the unfavourable dissolution kinetics and insufficient 
timeframe to allow complete dissolution of the drug, it is possible to realise 
that the melting event may mask the true thermodynamic solubility point 
(annealing temperatures at defined drug loadings). 
 
Analysis of Figure 10 shows that the value of χ becomes more negative for 
each plot as temperature is increased, which is again indicative of UCST 
behaviour  (24) . This finding holds particular significance since the region 
between 60-70% w/w felodipine-Soluplus was previously unidentified. Despite 
the improved sensitivity of the method detailed in this study, the liquid-solid 
transition curve could not be identified at drug loadings beneath 60% w/w. 
Figure 10 illustrates the discrepancies in the entropic (A) and enthalpic (B) 
contributions to χ as a result of methodology to determine the position of the 
liquid-solid transition curve. These values are essential for the completion of 
the equilibrium solubility curve to low drug loadings where experimental 
determination was not possible. Linearity was assumed in the dynamic 
method at drug loadings lower than 90% w/w felodipine content with a 
correlation coefficient (r2) of 0.99 being obtained. The new method of HME, 
annealing and HyperDSC exhibited linear behaviour at drug loadings less 
than 80% w/w FD producing an r2 value of 0.90.  
 
The dissolution/melting approach produced values of -14.419 and 5744.7 for 
A and B, respectively, whereas the combination of HME, annealing and 
HyperDSC determined these values of A and B as -11.163 and 4150.7, 
respectively. The liquid-solid transition curve for the new methodology was 
extrapolated to low drug loadings and its position can be compared to that of 
the previous approach in Figure 11a. It can be observed that lower 
experimental temperatures of the liquid-solid transition curve impacts 
significantly on the extrapolation to lower drug loadings. These findings can 
be attributed to the discrepancies in the entropic and enthalpic contributions to 
χ resulting from the plot in Figure 10. Furthermore, the position of the spinodal 
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curve was calculated using the second derivative of equation 4. A comparison 
of the positions of the spinodal curves for the new and dynamic 
methodologies can be found in Figure 11b.  
It can be observed that significant discrepancies in the respective positions of 
the spinodal curves exist at pharmaceutically relevant temperatures. For 
example, at a temperature of 25°C, the dynamic method predicted that a 
weight fraction of approximately 12% w/w FD would remain stable in the 
amorphous mixture, whereas the new methodology described here suggests 
a value of approximately 22% w/w. The spinodal curve provides an indication 
of the limit of thermodynamic metastability and its position provides a potential 
method for rational selection of drug weight fraction for a ASD formulation. As 
a result of more accurate determination of the position of the liquid-solid 
transition curve, and therefore the entropic and enthalpic contributions to χ, it 
is evident that that a larger weight fraction of FD may less susceptible to 
phase separation and crystallisation at pharmaceutically relevant 
temperatures than what was previously determined using the 
dissolution/melting point approach. 
The concept of introducing the theoretic spinodal curve is for the potential 
application of phase separation in the drug-polymer solid dispersion systems. 
It is imperative to aware that the apparent miscibility between amorphous drug 
and amorphous polymer (two liquids) is often much higher than the 
thermodynamic solubility (equilibrium) of the binary system. If we consider the 
crystallization of the drug from amorphous solid dispersion being two-step 
process, the liquid-liquid phase separation to form drug rich amorphous 
droplets would be the pre-courser for the crystallization of the drug from ASD. 
Therefore, the relevance of drug loading and temperature of the ASD at 
different positions of the phase diagram may be significantly altered resulting 
different mechanisms of liquid-liquid phase separation, i.e. the rate of phase 
separation will be different (spinodal vs. binodal). 
In this drug-polymer combination case, the liquid-solid line is above the whole 
theoretical spinodal curve. Therefore, from the pure thermodynamic point of 
view, when a system sits underneath the solubility curve, it is not equilibrium. 
The prepared ASD below the solid-liquid line (pharmaceutical relevant 
conditions) will undergo crystallization and/or phase separation as matter of 
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time (Figure 11a). However, when the polymer is involved in the ASD, the 
viscosity and potential low mobility of the system below the glass transition 
will also prolong the process of ASD returning to its equilibrium state, the 
mechanisms of which may be highly relevant to the position of binodal and 
spinodal curve.  
 
Significance of Pre-mixing via HME 
In order to demonstrate the importance of incorporating HME in the 
determination of crystalline equilibrium solubility, a physical mixture of 60% 
Felodipine-Soluplus was annealed at a temperature of 125°C for a period of 
24hours. Using fast scanning (define rate) after a period of isothermal 
annealing (define conditions) it is evident that residual FD crystal remained 
present within the system (data not shown). However, this temperature 
signified the upper boundary of the liquid-solid transition curve when an 
extruded sample of 60% FD-Sol containing crystalline was annealed at 
125°C. This finding demonstrates the importance of incorporating HME over 
ball milling in this methodology in order to overcome the effects of diffusive 
mixing/unfavourable kinetic conditions. Theoretically, if this ball-milled sample 
were annealed for an infinite period of time at 126°C, the residual FD crystal 
would eventually dissolve into the polymeric matrix as a result of the 
favourable thermodynamic conditions. However for the purpose of screening 
a polymer for ASD, using HME permits, imporved accuracy within a shorter 
experimental timeframe. 
 
General discussion 
In this study, a new approach has been presented for drug-polymer solubility 
determination in relation to HME platform, in which felodipine and Soluplus 
were mixed within a hot-melt extruder and annealed at elevated temperatures 
over a 24-hour period.  Subsequent high speed DSC scanning enabled the 
liquid-solid line to be defined more accurately than previous methods. In the 
original DSC dynamic approach, drug-polymer mixtures are commonly 
prepared via ball milling or cryomilling. This process will induce particle 
surface interaction and a degree of amorphous content.  However in this 
case, preparation of extrudates using a co-rotating extruder with full 
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conveying screw configuration resulted in significantly lower ΔHfus values 
required to melt the remaining crystalline drug content than those required 
after the process of ball milling (Figure 6). After annealing these samples for 
24 hours, it is extremely likely that if drug crystals remain, the annealing 
temperature does not signify the point of the liquid-solid transition curve, as 
this approach should provide ample time for drug dissolution to overcome the 
effects of polymer viscosity within the multiphase system.  
 
Selection of an extrusion temperature of 130°C resulted in the presence of 
felodipine crystals in the extrudate. This is an essential requirement of this 
approach since HyperDSC has been used to detect the boundaries of the 
liquid-solid transition curve based on the presence of felodipine crystals at a 
scan rate of 200°C/min. This heating rate provides enhanced sensitivity when 
compared to standard DSC heating rates, for example 1.0-10°C/min, and it 
will reduce the potential dissolution of the crystalline drug into the polymer 
providing a more accurate representation for the point of equilibrium solubility  
(30) . When constructing thermodynamic drug-polymer phase diagrams using 
the F-H theory, it is common that melting point depression data can only be 
detected for drug loadings ≥70% w/w. It may be possible to elucidate melting 
temperatures for lower drug loadings for systems that exhibit a limited degree 
of miscibility. It has previously been observed that felodipine–Soluplus 
possessed relatively favourable miscibility when compared to Felodipine-
HPMCAS. Melting point depression data could only be detected as low as 
70% w/w FD-Sol when a dynamic DSC method was utilised in comparison to 
55% w/w used in FD-HPMCAS [7]. Hence to further construct the phase 
diagram, a linear relationship between interaction parameter and temperature 
was assumed. However, by applying annealing and HyperDSC at scanning 
rates of 200°C/min, it was possible to experimentally determine the position of 
the liquid-solid transition curve at 60%FD w/w. It was observed that the 
relationship between χ and temperature remained linear in this previously 
undefined region. Ideally, experimental data for the liquid-solid transition curve 
could be detected across the entire range of possible drug loadings when 
applying this modified method with increased sensitivity. Before consideration 
of alternative polymeric carriers, it should be stressed that polymorphic 
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transformations of the crystalline drug are possible when processing in a hot-
melt extruder and adequate characterisation of the extrudates is essential 
post-processing to ensure that the correct polymorphic form of the drug exists 
within the excipient. One important point of note with regards to the 
methodology presented in this study is the amount of drug that is required. 
The process of HME in the Rondol Microlab requires approximately 5 grams 
of material for each composition. Preformulation studies will not always be 
performed with excess amounts of material (31) . If small amounts of drug are 
available and the purpose of collecting experimental data is purely to compare 
the extent of interaction between drug and polymeric excipients, the dynamic 
approach would suffice as long as the same conditions are applied across 
different drug-polymer combinations. However, for this study, key aims were 
to fully understand the difference between a dynamic approach and the 
thermodynamic equilibrium point of drug-polymer solid solution system, the 
relationship between thermodynamic miscibility and kinetic impact of process 
conditions.  Therefore it was essential to carry out HME as a pre-mixing step 
in order to understand the mechanism of this small-scale platform. 
Furthermore, it is recognised that the time taken for sample preparation with 
HME (residence time < 2 minutes) in this study is much quicker than typical 
ball mill and cryomill preparation and the yield after HME is high due to the 
self-wiping co-rotating screw design. Given the high level of mixing induced 
via the extrusion process and the extensive annealing step, this method will 
result in much more accurate calculations of drug solubility. This new 
approach will also enable polymer screening to take place, provided that drug-
polymer mixtures are given sufficient time above polymer Tg to reach 
equilibrium solubility. The detrimental effects of increasing viscosity as a result 
of high polymer content causing underestimations in melting point depression 
are also overcome using this methodology. Therefore, it is likely that 
equilibrium solubility of the drug in a polymeric excipient will be obtained in a 
shorter timeframe than 24 hours after being subjected to HME. This study has 
demonstrated, for the first time, the use of HME followed by extensive 
annealing and HyperDSC to overcome the limitations of a dynamic approach 
to probe the thermodynamic solubility of a small crystalline molecule within a 
high viscous polymeric carrier. This highly sensitive methodology will provide 
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a much more accurate depiction of the equilibrium solubility curve position as 
shown in Figure 8 and 11. It also demonstrated that the effects of kneading 
configuration and relevance to the drug composition and temperature for 
further mechanistic understanding of HME as a means of developing robust 
continuous manufacturing platforms for the production of stable amorphous 
solid dispersion systems. 
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CONCLUSION 
The development of an improved methodology in determining the position of 
the liquid-solid transition curve of a drug-polymer system and its relation to the 
use of hot-melt extrusion technology have been explored in this study. The 
limitations associated with detecting melting point depression data have been 
discussed at length where the effects of diffusive mixing and heating rate 
selection hinder the accuracy of traditional methods. In order to enhance the 
uniformity of felodipine-Soluplus® mixtures prior to processing using dynamic 
thermal analysis methods, we have demonstrated that HME can be 
incorporated to generate a multi-phase mixture with uniform dispersion. 
Design of Experiment (DoE) was employed to carry out a 2-level scope 
design so that drug-polymer uniform mixtures could be manufactured yet 
residual crystalline felodipine retained in the extrudate. Characterisation of the 
fresh extrudates containing 50-90% w/w feldopine were completed using a 
combination of Raman Spectroscopy, HyperDSC and PXRD. After validating 
the presence of crystalline FD (form I) in each of the samples, mixtures were 
annealed at various temperatures for a period of 24 hours to assess the 
thermodynamic solubility point. This process demonstrated the extent of the 
underestimation of FD solubility in Soluplus when utilising the dynamic DSC 
method. Subsequently, as a result of the increased sensitivity and accuracy, it 
was possible to define the relationship between χ and 1/T at lower drug 
loadings than previously reported. It was observed that a linear relationship 
between χ and 1/T exists at drug loadings ranging from 60-75% w/w 
felodipine-Soluplus system. Calculation of the entropic and enthalpic 
contributions to χ enabled extrapolation of the remainder of the liquid-solid 
transition curve below 60% w/w drug loading. Discrepancies between the 
positions of the FH predicted liquid-solid transition curves using each 
methodology were presented with a clear underestimation for dynamic 
heating approach being identified.  
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Table 1. A 2-level factorial design (Design Expert 9) for HME processing. The 
presence of crystalline FD within extrudates was identified using both HyperDSC and 
Raman spectroscopy. Materials were extruded at 130°C 
 
Run No. 
No. 90° 
Mixing 
Elements 
No. 60° 
Mixing 
Elements 
Screw 
Speed 
(rpm) 
Drug load  
(% w/w) 
Crystalline 
content 
1 0 3 30 50 No 
2 3 3 30 70 Yes 
3 0 0 11 50 Yes 
4 3 3 11 50 No 
5 3 0 30 50 No 
6 0 3 11 70 Yes 
7 3 0 11 70 Yes 
8 0 0 30 70 Yes 
 
 
Table 2. Selected annealing temperatures for extrudates containing 60-90% w/w FD. 
The upper boundary identifies the temperature where no crystalline FD was detected 
using HyperSC following 24 hours of annealing whilst the lower boundary signifies 
the temperature where a melting endotherm was present. 
 
Drug Load Annealing Temperature (°C) 
 (% w/w) Upper boundary (°C) Lower boundary (°C) 
90 139 137 
85 137 136 
80 136 134 
75 135 133 
70 133 130 
65 130 127 
60 126 123 
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 Figure 1. The illustration of thermodynamic drug-polymer solubility curve (solid 
line), measured “equilibrium” drug-polymer solubility curve via demixing method 
(short dash line) and measured “equilibrium” drug-polymer solubility curve via drug 
dissolution end point.  
 
 
 Figure 2: A plot of χ versus 1/T constructed using melting point depression data for 70-95% 
w/w FD-Sol mixtures processed at 1.0°C/min. Data taken from Tian et al. 2012 [7]. 
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Figure 3: Raman mapping images of FD-Soluplus® extrudates. 100% FD type I 
crystal was used as a reference spectra and varying degrees of FD crystals can be 
observed. Brightly shaded areas (white/pink) identify the presence of FD polymorph 
form I crystal. 
 
 
 
  
Figure 4: HDSC thermograms of freshly prepared extrudate containing 50-75% w/w 
FD completed using a heating rate of 200°C/min. 
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 Figure 5: PXRD diffractograpms of freshly prepared 50-65% w/w FD-Sol extrudates. 
 
 
  
Figure 6: DSC thermograms of ball milled physical mixtures and hot melt extruded 
formulations at a scanning rate of 1C/min (From top to bottom: 90% BM, 90% HME, 
85% BM, 85% HME, 80% BM and 80% HME w/w FD). 
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Figure 7: (a) HyperDSC thermograms of 65% (1-4) and 60% (5-7) w/w FD-Sol 
extruded samples before and after a period of 24 hours of annealing at elevated 
temperatures: fresh prepared HME of 65% (1) and 60% (5) FD-Solu, annealed at 125 
°C (2), 127 °C (3) and 130 °C (4) for 65%FD-Solu; annealed at 123 °C (6) and 125 °C (7) for 
60%FD-Solu; (8) pure polymer Soluplus (9) pure amorphous FD (b) The heatflow signal of 
65%FD-Solu annealed at 125 °C (1), 127 °C (2) and 130 °C (3); 60%FD-Solu annealed at 
123 °C (4) and 125 °C (5).   
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 Figure 8: A comparison between the positions of the liquid-solid transition curve calculated 
using melting point depression data from the dynamic method and the upper and lower 
boundaries of equilibrium solubility identified via HME, annealing and HDSC. 
 
  
Figure 9: Dynamic viscosities of 50-90% w/w FD-Sol physical mixtures after melting at 
145°C and cooling to 125°C at a rate of 5°C/min, oscillation stress of 5Pa and frequency of 
1Hz.  
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 Figure 10: Plots of χ versus 1/T for melting point depression data determined using 
the dynamic method and the midpoint values of the upper and lower boundaries of the 
experimentally determined liquid-solid transition curve using HME, annealing and 
HDSC. 
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Figure 11: (a) comparison between the positions of the extrapolated liquid-solid 
transition curves constructed using the respective A and B values taken from figure 
10; (b) calculated positions of the spinodal curves when adopting either the dynamic 
heating or HME, annealing and HyperDSC methodology. 
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